UCB and Immunomedics announce worldwide development collaboration and license agreement for Epratuzumab
11-May-2006 -
UCB and Immunomedics, Inc. announced a collaboration and license agreement for Immunomedics' lead product, epratuzumab. The agreement grants UCB the exclusive worldwide rights to develop, market and sell epratuzumab for all autoimmune disease indications. Epratuzumab's most advanced program is ...
autoimmune diseases
clinical trials
license agreements
+3